The topic of today's episode of NETCast is "Beyond Somatostatin Analogs." Our guest moderator is Dr. Junaid Arshad, Assistant Professor of Medicine and faculty member of GI Medical Oncology at the University of Arizona. Dr. Arshad received his medical degree from King Edward Medical University, Lahore, Pakistan and completed his Internal Medicine Residency at St. Mary's Hospital, Waterbury, CT. Dr. Arshad is a Clinical and Translational Scientist with a focus on developing novel therapeutics for several areas of Upper GI Oncology. He is a member of NANETS' Communications Committee. Dr. Arshad is joined by two distinguished NET medical experts: Dr. Emily Bergsland is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee. Dr. Pamela Kunz is an Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology; Vice Chief, Diversity, Equity, and Inclusion. Prior to joining Yale, Dr. Kunz was Director of the Stanford Neuroendocrine Tumor Program, Leader of the Endocrine Oncology Research Group, and Director of the Neuroendocrine Tumor Fellowship. She is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis. Dr. Kunz is the current president of the North American Neuroendocring Tumor Society. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.